drugset
drugset / Trial / NCT00248963

Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception

NCT00248963 ↗

Phase 3 Completed 600 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelEct

Summary

To evaluate the contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen and to evaluate the safety compared to LNG 100 mg/EE 20 mg for 21 days followed by a 7-day hormone-free interval in a cyclic regimen.

Timeline

Start
—
Primary completion
—
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 90 mg Oral
Subject Levonorgestrel Small molecule 100 mg Oral
Subject ethinyl estradiol Small molecule 20 mg Oral

Indications

No indication recorded.